Immunotherapy in Lung Cancer | Specialty

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

July 6th 2023

Expert perspectives on selecting between neoadjuvant and perioperative chemoimmunotherapy in patients with resectable early-stage NSCLC.

Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

July 6th 2023

Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.

Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

June 29th 2023

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

June 29th 2023

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Neoadjuvant Nivolumab/Chemo Wins EU Approval for Resectable PD-L1+ NSCLC

June 29th 2023

The European Commission has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer at high risk of recurrence with tumor cell PD-L1 expression of at least 1%.

Examining LIFU–Aided Liquid Biopsy in Glioblastoma: Raising the Bar With the LIMITLESS Trial

June 27th 2023

In this fourth episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, discuss the key objectives of the phase 3 LIMITLESS study (NCT05317858) examining low-intensity focused ultrasound with immunotherapy and chemotherapy in patients with lung cancer and brain metastases.

Selecting Optimal Treatment in Early-Stage NSCLC

June 23rd 2023

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview of Early-Stage NSCLC and Molecular Testing

June 23rd 2023

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

Investigators Set Sights on Immunotherapy for Long-Term Disease Control in NSCLC

June 9th 2023

Stephen V. Liu, MD, highlighted the importance of next-generation sequencing in lung cancer, key trials that have shifted the non–small cell lung cancer treatment landscape, and detailed ongoing research at Georgetown University Lombardi Comprehensive Cancer Center.

Pembrolizumab Plus Chemo Does Not Significantly Improve Survival in TKI-resistant, EGFR+ NSCLC

June 6th 2023

The addition of pembrolizumab to pemetrexed and platinum-based chemotherapy resulted in a numerical, but not statistically significant, improvement in progression-free survival or overall survival vs chemotherapy plus placebo in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer.

Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC

June 3rd 2023

The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.

Combination Chemotherapy and Immunotherapy for Advanced NSCLC

May 23rd 2023

Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.

The Evolution of Chemoimmunotherapy in Advanced NSCLC

May 23rd 2023

Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

May 19th 2023

John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.

Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLC

May 18th 2023

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC

May 16th 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.

Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

May 16th 2023

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

May 9th 2023

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

May 9th 2023

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Updates in Gender-Based Treatment for Patients with Advanced NSCLC

May 2nd 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.